RobertODillmanMD

Chief Medical Officer of AiVita Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc.

Join to view full profile

Dr. Dillman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dillman's full profile

Already have an account?

Office
1 Hoag Dr
Bldg Cancer
Newport Beach, CA 92663
Phone+1 949-764-8091

Fax+1 949-764-8102

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1980
Baylor College of MedicineResidency, Internal Medicine, 1974 - 1978
Baylor College of MedicineClass of 1973

Certifications & Licensure

CA State Medical License 1978 - 2026
TX State Medical License 1974 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Tumor Cell Vaccine in Treating Patients With Advanced Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Start of enrollment: 1992 Aug 01
Completed
Phase 2
Biological Therapy in Treating Patients With Metastatic Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 2
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma Start of enrollment: 1996 Jan 01
Completed
Phase 2
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma Start of enrollment: 1998 May 01
Withdrawn
Phase 2
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Vaccine Therapy in Treating Patients With Kidney Cancer Start of enrollment: 2001 Nov 01
Terminated
Phase 1
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Start of enrollment: 2002 Jun 01
Completed
Phase 2
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme Start of enrollment: 1999 Feb 01
Completed
Phase 2
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2006 Dec 01
Completed
Phase 2
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2008 Nov 01
Withdrawn
Phase 2
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells Start of enrollment: 2000 Oct 01
Completed
Phase 2
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Start of enrollment: 2014 Oct 01
Terminated
Phase 3
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Start of enrollment: 2017 Nov 18
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

27 citations
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Daniela A Bota, Thomas H Taylor, David E Piccioni, Christopher M Duma, Renato V LaRocca
Journal of Experimental & Clinical Cancer Research. 2022-12-14
4 citations
A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses.
Gabriel I Nistor, Robert O Dillman, Rockelle M Robles, James L Langford, Aleksandra J Poole
Human Vaccines & Immunotherapeutics. 2022-11-30
11 citations
An update on GM-CSF and its potential role in melanoma management.
Robert O Dillman
Melanoma Management. 2020-07-29

Lectures

Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy CongressNovember 29th, 2022
AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022October 12th, 2022
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of Its COVID-19 Vaccine CandidateAugust 29th, 2022
Join now to see all